NCT06967987
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06967987
Title Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b (BEMAFLOT)
Acronym BEMAFLOT
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut Cancerologie de l'Ouest
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
Institut de Cancérologie de l'Ouest Angers 49055 France Details
Institut Bergonié Bordeaux 33000 France Details
CHRU de Brest Brest 29609 France Details
Centre François Baclesse Caen 14076 France Details
Centre Georges François Leclerc Dijon 21079 France Details
Centre Léon Bérard Lyon 69373 France Details
Institut Paoli Calmette Marseille 13273 France Details
CHU de Poitiers Poitiers 86021 France Details
CHU de Rennes Rennes 35000 France Details
Institut de Cancérologie de l'Ouest Saint-Herblain 44805 France Details
Institut de Cancérologie de Lorraine Vandœuvre-lès-Nancy 54519 France Details
Gustave Roussy Villejuif 94805 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field